Navigation Links
Portola Pharmaceuticals Announces Positive Phase II EXPERT Results,and Additional Oral and Poster Presentations at the XXI Congress of,the International Society on Thrombosis and Haemostasis (ISTH)

SOUTH SAN FRANCISCO, July 02, 2007 /PRNewswire/ -- Portola Pharmaceuticals, Inc. announced today that it will present clinical and preclinical data on its oral Factor Xa inhibitor and on its intravenous and oral ADP receptor antagonist at the XXI Congress of the International Society of Thrombosis and Haemostasis (ISTH) in Geneva, Switzerland on July 6 through July 12, 2007.

The EXPERT poster, which outlines Phase II data on the Company's lead compound PRT054021, is entitled "Evaluation of the Factor Xa (FXA) Inhibitor, PRT054021 (PRT021), against Enoxaparin in Randomized Trial for the Prevention of Venous Thromboembolic Events after Total Knee Replacement (EXPERT)" and will be featured on July 10, 2007 at 5:30 p.m. CEST in the exhibition area.

    In addition, Portola will make the following presentations:


     "Initial Intravenous Experience with PRT060128 (PRT128), an Orally-

     Available, Direct-Acting, and Reversible P2Y12 Inhibitor," July 10 at

     5:30 p.m. (CEST) in the exhibition area.


     "PRT060128, A Novel, Direct-Acting Orally Available P2Y12 Antagonist,

     Confers Superior Antithrombotic Activity over Clopidogrel in a Mouse

     Thrombosis Model," July 11 at 10:00 a.m. (CEST) in Room Mont Blanc.


     "Differential Effects of Anti-Platelet Drugs on Thrombus Formation and

     Thrombus Stability," July 11, 2007 at 10:45 a.m. (CEST) in Room Mont

     Blanc.


     "Antagonism of Intrinsic Pathway Inhibits Tissue Factor (TF) -- Initiated

     Coagulation in a Platelet-Dependent Whole Blood Flow Assay" July 11 at

     5:30 p.m. (CEST) in the exhibition area.


     "Measurement of Thrombus Stability Predicts Coronary Events Post-

     Percutaneous Coronary Intervention (PCI)" will be presented on July 11 at

     5:30 p.m. (CEST) in the exhibition area.

About PRT054021 -- Portola's Factor Xa Inhibitor

PRT054021 is an oral Factor Xa inhibitor, an a
'"/>




Page: 1 2 3

Related medicine technology :

1. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Portola Pharmaceuticals Announces Positive Phase II Results for PRT054021 for Prevention of Venous Thromboembolism Following Total Knee Replacement Surgery
3. Portola Pharmaceuticals Presents Positive Phase I Data of Its ADP Receptor Antagonist at the American College of Cardiology
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
10. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
11. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
Post Your Comments:
(Date:10/8/2008)...ornell University Food Scientists Expand Testing U...tivity Assay, PORTLAND, Maine, Oct. 8 /PRNewswire...today with the release of results from a new study...er commonly consumed,fruits like apples, bananas, ...ing the Cellular Antioxidant Activity (CAA) assay....
(Date:10/8/2008)...N, France, Oct. 8 /- Vical Incorporat...linical data and new nonclinical data,demonstratin...broadly,applicable in DNA- and protein-based infec...ccines. Alain P. Rolland, Pharm.D., Ph.D., Vical,s...l present the data today,Wednesday, October 8, at...
(Date:10/7/2008)...NT, Mich., Oct. 7 /- McLaren Health C...ring some of the world,s leading medical,minds to ... breast and,gastrointestinal cancer treatments. Th...CI, was organized by McLaren,s Sukamal Saha, M.D.,...n sentinel node mapping for,colorectal cancer has ...
(Date:10/7/2008)...ults of FLEXX Trial Presented at the Osteoarthriti...ress, PARSIPPANY, N.J., Oct. 7 /- Fe...lts from the FLEXX Trial of Osteoarthritis of the,...ate), a highly pure,non-avian high molecular weigh... is superior to intra-articular saline (IA-saline)...
Breaking Medicine Technology:Wild Blueberries Take Top Spot in New Antioxidant Research Study 2Wild Blueberries Take Top Spot in New Antioxidant Research Study 3Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 2Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 3Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 4Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 5News Media Advisory: World's Leading Surgical Oncologists to Gather at McLaren Regional Medical Center to Present Latest Work on Breast, Gastrointestinal Cancer Treatments 2Study Shows EUFLEXXA(R) Patients Report Significant Improvements in Osteoarthritis of the Knee Pain over a Six Month Period 2Study Shows EUFLEXXA(R) Patients Report Significant Improvements in Osteoarthritis of the Knee Pain over a Six Month Period 3Study Shows EUFLEXXA(R) Patients Report Significant Improvements in Osteoarthritis of the Knee Pain over a Six Month Period 4IDM Pharma Announces Upcoming Clinical Data Presentations 674 1IDM Pharma Announces Upcoming Clinical Data Presentations 674 2IDM Pharma Announces Upcoming Clinical Data Presentations 674 3IDM Pharma Announces Upcoming Clinical Data Presentations 674 4Cadence Pharmaceuticals CEO Theodore Schroeder to Present at BIOCOM Investor Conference 2007 1521 1Cadence Pharmaceuticals CEO Theodore Schroeder to Present at BIOCOM Investor Conference 2007 1521 2ASA San Diego Offers Resources and Information to Families with Autism in Wake of Fires 4675 1ASA San Diego Offers Resources and Information to Families with Autism in Wake of Fires 4675 2Kosan to Reacquire Epothilone Program From Roche 1518 1Kosan to Reacquire Epothilone Program From Roche 1518 2Kosan to Reacquire Epothilone Program From Roche 1518 3Kosan to Reacquire Epothilone Program From Roche 1518 4
...linical study of,HGS-ETR1 -, ROCKVILLE, Md., April...ciences, Inc. today reported that clinical and pre...g that its TRAIL receptor,antibodies, HGS-ETR1 (ma...icant potential for use in the treatment of a broa...d HGS-ETR2 could offer novel, highly,targeted ther...
...llaGenex,Pharmaceuticals, Inc. (NASDAQ:CGPI) today... of the Journal of the American Academy,of Dermato...trials,demonstrated the efficacy and safety of an... doxycycline, USP capsules) for the,treatment of r...tablish the first important body of evidence suppo...
Other Medicine Technology:Human Genome Sciences Reports Growing Evidence That Its TRAIL,Receptor Antibodies Have Significant Potential in the Treatment of,a Broad Range of Cancers 2Human Genome Sciences Reports Growing Evidence That Its TRAIL,Receptor Antibodies Have Significant Potential in the Treatment of,a Broad Range of Cancers 3Human Genome Sciences Reports Growing Evidence That Its TRAIL,Receptor Antibodies Have Significant Potential in the Treatment of,a Broad Range of Cancers 4Human Genome Sciences Reports Growing Evidence That Its TRAIL,Receptor Antibodies Have Significant Potential in the Treatment of,a Broad Range of Cancers 5Evaluating the Efficacy and Safety of Once-Daily Anti-Inflammatory,Dose Doxycycline for the Treatment of Rosacea 2Evaluating the Efficacy and Safety of Once-Daily Anti-Inflammatory,Dose Doxycycline for the Treatment of Rosacea 3Evaluating the Efficacy and Safety of Once-Daily Anti-Inflammatory,Dose Doxycycline for the Treatment of Rosacea 4
(Date:10/12/2008)... Birdstep Technology,s high availability embedded ...carrier grade OSE RTOS. , ...Technology (OSE: BIRD) today announced the release...ing system. This is the latest platform to be adde...d platforms., , ,"We recognized the importanc...
(Date:10/11/2008)...ould Not Pose Setback and Expects the 89-Year-Old ... ASHEVILLE, N.C., Oct. 11 /PRNewswire/ -- Evangeli...in Montreat, N.C. upon his release this,afternoon ...g a brief stay.,He was admitted for observation af... late Friday., Mr. Graham,s physicians said that ...
(Date:10/11/2008)...ernational Transcends Cultural Divides, JOHANNESB...frican and,international audiences welcome Bishop ...fying gathering, which for the first time is being...tp://www.newscom.com/cgi-bin/prnh/20081011/CLSA011...off with performances by,South Africa,s own multi-...
(Date:10/10/2008)... those already on drugs, some diagnoses could be w...althDay News) -- A new study questions the commonl...e ( C. difficile ) infections are always preceded ...iversity and the Jewish General Hospital found tha...cquired C. difficile infections before hospitali...
Breaking Medicine News(10 mins):Health News:Birdstep Technology Adds ENEA's OSE RTOS to the List of Operating Systems Supported by Their RDM Server, Embedded Database Product 2Health News:Billy Graham Returns Home Following Hospital Observation 2Health News:Bishop T.D. Jakes Electrifies South Africa 2Health News:Antibiotics May Not Cause Diarrheal Bacteria 2
...yan governmment said Tuesday the rate of HIV/AIDS ...e still posed a a major challenge in the country....CC) said the rate fell from 6.1 percent in 2004 to...nt of the country's nearly 35 million people. "Of...
...etic version of a molecule found in the egg cells ...provide the world with the first drug treatment fo...es the sugary coating found on a tumour cell and b... invading the cell and inactivating the RNA it con...
...s is understood as the perception of noise in the ...nal source of sound, without any vibratory cochlea...rnal noise is produced). It is estimated that bet...uffered tinnitus at some time in their lives, acco...
...t study has found that a substance derived from th...rtain kinds of cancer cells. The study, conducte...ested that this substance could lead to a novel tr...mmon type of lung cancer. The compound, called be...
Other Medicine News:Health News:Brain Tumor Drug in Frogs A New Report 2Health News:Tinnitus Patients can Lead a Normal Life 2Health News:Tinnitus Patients can Lead a Normal Life 3Health News:Tinnitus Patients can Lead a Normal Life 4Health News:Tinnitus Patients can Lead a Normal Life 5Health News:Tree Bark Substance may Hold New Lung-cancer Treatment 2
...mory capabilities for overnight sleep screening.,...turation and pulse rate data, and can operate in t...,1. The Model 130 can retain up to 30 minutes of...ce ideally suited for treadmill or other long-dura...
...d Pulse Oximeter provides SpO 2 and pulse rate mo...evice is battery or AC powered, has adjustable ala...gnals, and an infrared link to a printer (catalog ...for added protection. The digital technology util...
The FingerPrint Pulse Oximeter is a low cost Hand-Held Pulse Oximeter with an integral printer. A light-weight, highly portable device providing SpO 2 and pulse rate measurements, it has easy-to-re
...oring system compatible with personal computers or...d and cost-effective.The BCI 3301 HAND-HELD PULSE ...try wherever spot-checking is needed... including ...spitals. In fact, its ergonomic design, easy-to-re...
Medicine Products: